Literature DB >> 32681462

Pituitary neuroendocrine tumors and differentiated thyroid cancer: do metabolic and inflammatory risk factors play roles?

G Cortês Nascimento1,2,3, A G P de Araujo Cortês Nascimento4,5,6, C de Maria Ribeiro Veiga Parente7, V P Rodrigues5,8, R S de Sousa Azulay7,4,5, V C de Carvalho Rocha7,4,5, S da Silva Pereira Damianse7,4,5, M Magalhães4,5, M Dos Santos Faria7,4,5, M B Gomes9.   

Abstract

PURPOSE: It is postulated that patients with different types of pituitary neuroendocrine tumors (PitNETs) may present a higher incidence of cancer. Factors underlying individuals becoming overweight, such as insulin resistance, hyperleptinemia, and low-grade inflammation, may play a role in the risk of differentiated thyroid carcinoma (DTC) in such patients. This study aimed to investigate the frequency of and obesity-related risk factors associated with DTC in patients with PitNETs.
METHODS: This cross-sectional study involved 149 patients with nonacromegalic PitNETs (AG group), 71 patients with acromegaly (ACRO group), and 156 controls (CG group). All participants underwent insulin and blood glucose measurements with the determination of the homeostatic model assessment-insulin resistance (HOMA-IR) index, leptin, and high-sensitivity C-reactive protein (hsCRP), and they also underwent thyroid ultrasound. Clinically significant nodules were biopsied for subsequent cytopathological evaluation, and participants were operated on when indicated.
RESULTS: Patients in the AG group had high levels of insulin resistance and significantly higher levels of leptin and hsCRP compared with those of patients in the ACRO group. There were no cases of DTC in the AG group; two findings, one incidental, of DTC occurred in the CG group, and three cases of DTC were present in the ACRO group. Acromegaly was associated with DTC after adjusted analysis.
CONCLUSIONS: Our findings in patients with nonacromegalic PitNETs do not indicate a high risk for DTC despite the presence of metabolic and inflammatory risk factors for neoplastic events. In contrast, acromegaly promotes a greater risk of DTC.

Entities:  

Keywords:  Acromegaly; Insulin resistance; Leptin; Low-grade inflammation; Pituitary tumors; Thyroid cancer

Year:  2020        PMID: 32681462     DOI: 10.1007/s40618-020-01357-8

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  36 in total

1.  Acromegaly is associated with increased cancer risk: a survey in Italy.

Authors:  Massimo Terzolo; Giuseppe Reimondo; Paola Berchialla; Emanuele Ferrante; Elena Malchiodi; Laura De Marinis; Rosario Pivonello; Silvia Grottoli; Marco Losa; Salvatore Cannavo; Diego Ferone; Marcella Montini; Marta Bondanelli; Ernesto De Menis; Chiara Martini; Efisio Puxeddu; Antonino Velardo; Alessandro Peri; Marco Faustini-Fustini; Patrizia Tita; Francesca Pigliaru; Giulia Peraga; Giorgio Borretta; Carla Scaroni; Nicoletta Bazzoni; Antonio Bianchi; Alessandro Berton; Andreea Liliana Serban; Roberto Baldelli; Letizia Maria Fatti; Annamaria Colao; Maura Arosio
Journal:  Endocr Relat Cancer       Date:  2017-07-14       Impact factor: 5.678

2.  Incidence of malignant tumours in patients with a non-functioning pituitary adenoma.

Authors:  Daniel S Olsson; Casper Hammarstrand; Ing-Liss Bryngelsson; Anna G Nilsson; Eva Andersson; Gudmundur Johannsson; Oskar Ragnarsson
Journal:  Endocr Relat Cancer       Date:  2017-03-08       Impact factor: 5.678

3.  Cancer Incidence in Patients With Acromegaly: A Cohort Study and Meta-Analysis of the Literature.

Authors:  Jakob Dal; Michelle Z Leisner; Kasper Hermansen; Dóra Körmendiné Farkas; Mads Bengtsen; Caroline Kistorp; Eigil H Nielsen; Marianne Andersen; Ulla Feldt-Rasmussen; Olaf M Dekkers; Henrik Toft Sørensen; Jens Otto Lunde Jørgensen
Journal:  J Clin Endocrinol Metab       Date:  2018-06-01       Impact factor: 5.958

Review 4.  MANAGEMENT OF ENDOCRINE DISEASE: Acromegaly and cancer: an old debate revisited.

Authors:  Cesar Luiz Boguszewski; John Ayuk
Journal:  Eur J Endocrinol       Date:  2016-04-18       Impact factor: 6.664

5.  Thyroid cancer in patients with acromegaly: a case-control study.

Authors:  Maíra Cristina Carvalho dos Santos; Gilvan Cortês Nascimento; Ana Gisélia Cortês Nascimento; Viviane Chaves Carvalho; Maria Honorina Cordeiro Lopes; Renan Montenegro; Renan Montenegro; Lucio Vilar; Mônica Fiterman Albano; Alice Regina Vasconcelos Alves; Conceição Veiga Parente; Manuel dos Santos Faria
Journal:  Pituitary       Date:  2013-03       Impact factor: 4.107

6.  Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis.

Authors:  Theodoros Rokkas; Dimitrios Pistiolas; Panos Sechopoulos; Georgios Margantinis; Georgios Koukoulis
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

Review 7.  The prevalence of pituitary adenomas: a systematic review.

Authors:  Shereen Ezzat; Sylvia L Asa; William T Couldwell; Charles E Barr; William E Dodge; Mary Lee Vance; Ian E McCutcheon
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

Review 8.  Biological mechanisms linking obesity and cancer risk: new perspectives.

Authors:  Darren L Roberts; Caroline Dive; Andrew G Renehan
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

Review 9.  GH therapy and cancer risk in hypopituitarism: what we know from human studies.

Authors:  Sandra Pekic; Vera Popovic
Journal:  Eur J Endocrinol       Date:  2013-10-01       Impact factor: 6.664

Review 10.  Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review.

Authors:  Kosma Wolinski; Agata Czarnywojtek; Marek Ruchala
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.